Genmab: shares up as J&J files drug application with FDA
(CercleFinance.com) - Shares in Danish biotech Genmab are up over 2% on Tuesday after its partner Johnson & Johnson submitted an application to the FDA for the use of Darzalex as treatment for newly diagnosed patients with multiple myeloma.
Genmab said that Janssen, a J&J unit, has submitted a supplemental Biologics License Application (sBLA) to the Food and Drug Administration for a combination of Darzalex and other drugs as treatment for patients with multiple myeloma who are candidates for autologous stem cell transplant.
For the record, Genmab has granted Janssen an exclusive worldwide license to develop, manufacture and commercialize Darzalex.
This intravenous drug triggers a person's own immune system to attack the cancer cells, resulting in rapid tumor cell death.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Genmab said that Janssen, a J&J unit, has submitted a supplemental Biologics License Application (sBLA) to the Food and Drug Administration for a combination of Darzalex and other drugs as treatment for patients with multiple myeloma who are candidates for autologous stem cell transplant.
For the record, Genmab has granted Janssen an exclusive worldwide license to develop, manufacture and commercialize Darzalex.
This intravenous drug triggers a person's own immune system to attack the cancer cells, resulting in rapid tumor cell death.
Copyright (c) 2019 CercleFinance.com. All rights reserved.